LGD-4033 vs Oxytocin
Moderate Research vs FDA Approved
monitor Mechanism-based · 51% Both LGD-4033 and Oxytocin can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
LGD-4033 Oxytocin
Weight 338.25 Da 1,007.19 Da
Half-life ~24-36 hours 3-6 minutes
Chain — 9 amino acids
Type Nonsteroidal selective androgen receptor modulator (C14H12F6N2O) Cyclic nonapeptide
Key Benefits
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Oxytocin
01 FDA-approved for labor induction with precise dosing via IV
02 Immediate onset in obstetric settings
03 Established safety profile in clinical use
04 Researched for anxiety, PTSD, autism, sexual dysfunction
Dosing Protocols
LGD-4033
5-10 mg/day / Once daily (oral)
Oxytocin
Intranasal: 20-24 IU; Injectable: 10-40 IU; Sublingual: 50-100 IU / As needed for social/sexual support, or 1-2x daily for anxiety/PTSD protocols; max 1 dose per 24hr for sexual function
Labor Induction 0.5-2 mU/min initial, titrate to 1-2 mU/min every 30-60 min Continuous IV infusion
Postpartum Hemorrhage Prevention 10 units IM or 10-40 units in IV solution Single dose after placental delivery
Side Effects
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Oxytocin
Mild headache
Nasal irritation (intranasal)
Nausea or vomiting
Transient blood pressure changes
Contraindications
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Certain obstetric conditions (see prescribing info)
Pregnancy (without medical supervision)
Active sinus infection (intranasal)
Severe hyponatremia
Research Evidence
LGD-4033 Oxytocin
Status Moderate Research FDA Approved
References 5 studies 3 studies
Latest 2018 —
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.